Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218823 · ClinicalTrials.gov registry record · Phase 4
Tobacco Treatment Comparison for Cancer Care
A Phase 4 study of Cancer and Smoking Cessation, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06218823 is a Phase 4 study of Cancer and Smoking Cessation that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 52 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06218823, a Phase 4 study of Cancer and Smoking Cessation, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline treatment and 7 smoking cessation coaching calls with a cancer focus will be compared against an active comparator modeled after standard quitline treatments (2 weeks of nicotine patch therapy with 3 phone coaching calls). Approximately 50 participants will be recruited to generate estimates of the effects, acceptability, costs, and equity of enhanced treatment (vs. standard treatment), with the primary outcome being abstinence from smoking 26 weeks after trying to quit.
Conditions Studied
Interventions
- DRUG Varenicline
- DRUG Transdermal Nicotine Patch
- BEHAVIORAL Standard Telephone Counseling
- BEHAVIORAL Cancer-Targeted Telephone Counseling
- OTHER Mailed Information about Standard Care Resources
Study Locations (1)
Wisconsin
- UW Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-08-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06218823
The ClinicalTrials.gov registry entry for NCT06218823 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Varenicline is the first listed.
NCT06218823 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06218823 about?
NCT06218823 is a clinical study titled "Tobacco Treatment Comparison for Cancer Care". This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the past 3 years. An enhanced treatment comprising 12 weeks of varenicline...
What is the current status of trial NCT06218823?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2024-03-01. Estimated completion is 2025-08-04.
What conditions does trial NCT06218823 study?
This clinical trial studies the following conditions: Cancer, Smoking Cessation.
What interventions are being tested in trial NCT06218823?
The interventions under investigation include: Varenicline (DRUG), Transdermal Nicotine Patch (DRUG), Standard Telephone Counseling (BEHAVIORAL), Cancer-Targeted Telephone Counseling (BEHAVIORAL), Mailed Information about Standard Care Resources (OTHER).
Who is sponsoring clinical trial NCT06218823?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218823 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
COMPLETED · Phase 4
-
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
COMPLETED · Phase 4
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.